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Objective: Several practice guidelines recommend routine screening for psychological distress in cancer care. The
objective was to evaluate the effect of screening cancer patients for psychological distress by assessing the
(1) effectiveness of interventions to reduce distress among patients identiﬁed as distressed; and (2) effects of
screening for distress on distress outcomes.
Methods: CINAHL, Cochrane, EMBASE, ISI, MEDLINE, PsycINFO, and SCOPUS databases were searched through
April 6, 2011 with manual searches of 45 relevant journals, reference list review, citation tracking of included
articles, and trial registry reviews through June 30, 2012. Articles in any language on cancer patients were
included if they (1) compared treatment for patients with psychological distress to placebo or usual care in a
randomized controlled trial (RCT); or (2) assessed the effect of screening on psychological distress in a RCT.
Results: There were 14 eligible RCTs for treatment of distress, and 1 RCT on the effects of screening on patient
distress. Pharmacological, psychotherapy and collaborative care interventions generally reduced distress with
small to moderate effects. One study investigated effects of screening for distress on psychological outcomes,
and it found no improvement.
Conclusion: Treatment studies reported modest improvement in distress symptoms, but only a single eligible
study was found on the effects of screening cancer patients for distress, and distress did not improve in screened
patients versus those receiving usual care. Because of the lack of evidence of beneﬁcial effects of screening can-
cer patients for distress, it is premature to recommend or mandate implementation of routine screening.© 2013 Elsevier Inc. All rights reserved.Introduction
Emotional distress is common among cancer patients as a result of the
diagnosis of a life-threatening disease, aggressive medical treatments,
changes in lifestyle that occur, and the direct effects of the tumor [1–3].
Increasingly, attention is being paid to the psychological consequences333 Cote Ste Catherine Road;
8222x5112; fax: +1 514 340
s).
rights reserved.of cancer, with recognition of not only psychiatric disorders such as
major depressive disorder (MDD) or anxiety disorders, but also of
subsyndromal symptoms of depression and anxiety. In addition, attention
is being paid to the broader and more inclusive concept of emotional or
psychological distress, as indicated by an elevated score on a one-item
distress thermometer or another psychological symptom questionnaire.
A number of major cancer organizations have recommended routine
screening for distress, broadly deﬁned, and several accrediting agencies
mandate routine distress screening on the assumption that identiﬁcation
of distress will result in increased uptake of services and reductions in
distress [4–6].
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as an intervention that involves the application of a screening tool to
individuals who are not otherwise aware they are at risk, in order to
detect a medical condition that can be alleviated through intervention
[7,8]. Screening for MDD, for instance, involves the use of depression
symptom questionnaires or small sets of questions about depression
to identify patients who may have depression, but who have not
sought treatment and whose depression has not already been recog-
nized by healthcare providers. Patients identiﬁed as possible cases
based on a positive screen need to be further assessed to determine
if they have depression and, if appropriate, offered treatment [9].
Screening for “distress” is less well-deﬁned since it does not seek to
identify patients with a medical condition, and the meaning of a positive
screen is less clear. If screening for “distress” is to be done, nonetheless,
consistent with well-established deﬁnitions of screening [7,8], it would
involve using scores above a pre-deﬁned cutoff on a distress screening
tool to identify patients to be offered an intervention to reduce psycholog-
ical distress. Distress screening would be potentially useful if it could im-
prove patient outcomes beyond existing standard care in which patients
had access to the same services without being screened.
Three previous reviews [10–12] have sought to evaluate whether
there is evidence that routine screening for psychological distress im-
proves psychosocial outcomes among patients with cancer. The
reviews have concluded that screeningmay improve communication be-
tween patients and health care providers and may stimulate discussions
of psychosocial and mental health issues. The reviews agreed, however,
that there is not conclusive evidence that screening for distress improves
patient outcomes. One concern about these reviews is that they included
studies that would not be considered “screening” based on any standard
deﬁnition of screening. For example, some included studies used psycho-
social questionnaires to inform psycho-oncology consultations that were
provided to all patients. This is not screening, however, which, by deﬁni-
tion, would involve using the questionnaires to actually determine which
patients would receive the psychosocial consultations and potentially be
offered psychosocial services [7–9].
In a previous systematic review, we considered the evidence on
screening for MDD in cancer patients [13], but did not ﬁnd evidence
to support recommendations of systematic screening for depression.
Compared to depression, the target of recommendations for screen-
ing for psychological distress is broader in scope, but less clearly
deﬁned in terms of targeting a speciﬁc medical condition. The objec-
tive of the present systematic review was to evaluate the evidence on
screening for psychological distress in cancer. Review questions were
developed based on the U.S. Preventive Services Task Force (USPSTF)
[14,15] analytic framework for evaluating screening programs. The
USPSTF framework recognizes the need for RCTs to directly assess
links between screening programs and patient outcomes. When di-
rect evidence from screening RCTs is not available or is of low quality,
the USPSTF framework assesses key links that are necessary for
screening to beneﬁt patients, such as the availability of effective treat-
ments [14,15].
Screening for distress per se differs from other medical screening
programs in that there is not a clear, deﬁned medical condition, such
as MDD, that screening tools seek to detect. Thus, although reviews of
screening usually assess screening tool accuracy compared to a gold
standard [14,15],wewere not able to do this. Nonetheless, an important
prerequisite if screening of psychological distress is to improve patient
outcomes is that distress can be reduced through intervention for
patients identiﬁed as distressed. Thus, consistentwithUSPSTFmethods,
Review Question #1 was, “What are the effects of interventions to
reduce distress among cancer patients who have been selected for
treatment based on a minimum threshold of psychological distress, as
would be done in a screening program?” If screening is to be actually
recommended as policy, there should be consistent evidence from well-
conducted randomized controlled trials (RCTs) [16,17] that screening
beneﬁts patients in excess of any possible harms. Thus, Review Question#2 was, “Is routine screening for psychological distress of cancer patients
more effective than usual care in reducing symptoms of distress?”
Methods
Search strategy
The CINAHL, Cochrane, EMBASE, ISI, MEDLINE, PsycINFO, and
SCOPUS databases were searched through April 6, 2011. A search
was conducted for studies of interventions designed to reduce psy-
chological distress among cancer patients identiﬁed as having dis-
tress (Review Question #1) and for studies that assessed outcomes
of psychological distress screening interventions (Review Question
#2). Search terms are reported in Appendix A. Manual searches
were done on relevant systematic reviews (Appendix B), reference
lists of included articles, and 45 selected journals (March 2011 to
May 2012; Appendix C). We also tracked citations of included arti-
cles using Google Scholar [18] and searched the trial registries
ClinicalTrials.gov [19] and the International Standard Randomized
Controlled Trial Number Register [20] to attempt to identify unpublished
treatment or screening RCTs.
Identiﬁcation of eligible studies
Eligible articles included studies in any language on cancer pa-
tients with any type of malignancy at any disease stage that reported
original data, excluding abstracts, case series, or case reports. Transla-
tors assisted reviewers to evaluate titles and abstracts and full-length
articles for languages not covered by investigators, who were able to
independently review material in English, Dutch, French, and Spanish.
Multiple articles from the same cohort were treated as a single study.
Studies with mixed populations were included only if cancer data
were reported separately.
For Review Question #1, eligible articles were RCTs that compared
interventions designed to reduce psychological distress to placebo,
usual care, or attention controls in adult cancer patients with elevated
distress. Only RCTs that limited inclusion to patients with high levels of
distress, rather than all patientswith cancer,were included because this
is what would occur in a screening program. Indeed, patients with low
levels of distress experience only negligible beneﬁts from psychosocial
interventions in cancer settings [21]. Small, underpowered studies are
often of poor quality, and signiﬁcant publication bias is amajor problem
among these studies [22–24]. A number of proposals have been made
regarding setting thresholds for minimum number of patients for
studies to be included in systematic reviews [23,24]. In the present
review, we included trials that randomized at least 25 patients to
each group [25]. Head-to-head comparisons of different interventions
without a comparison to usual care or placebo were not eligible. De-
tailed eligibility criteria that were used for determining study eligibility
are shown in Appendix D.
Eligible articles for Review Question #2 were RCTs that compared
outcomes between cancer patients who underwent screening for psy-
chological distress and those who did not. Screening was deﬁned
according to the UK National Screening Committee's deﬁnition [7].
Thus, eligible screening trials had to include a strategy to identify pa-
tients with high levels of psychological distress based on an a priori-
deﬁned cutoff score on a measure of distress. Furthermore, in eligible
studies, positive versus negative results of the screening test had to be
used to make decisions about further assessment, referral, or treatment.
Studies were excluded if questionnaires were used to inform and struc-
ture conversations that occurred as part of psychosocial consultations,
but not to determine which patients receive services to address distress
based on a score above a pre-deﬁned cutoff. Finally, studies that involved
administering multiple screening tools for multiple problems were
not included, since patients in these studies could have been deemed
in need of services due to reasons other than psychological distress
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tion and parking, or nutritional needs) [26], and determining whether
the psychological distress component of screening inﬂuenced distress
outcomes would not be possible.
Two investigators independently reviewed articles for eligibility. If
either deemed an article potentially eligible based on title and abstract
review, then a full-text review was undertaken. Disagreements after
full-text review were resolved by consensus.
Evaluation of eligible studies
Two investigators independently extracted and entered data into a
standardized spreadsheet (seeAppendix E). Discrepancieswere resolved
by consensus. Risk of bias in studies included for both review questions
was assessed with the Cochrane Risk of Bias tool [27] (see Appendix F),
including assessment of ﬁnancial conﬂicts of interest as has been
recommended [28,29]. Risk of bias was assessed by two investigators,
with discrepancies resolved by consensus.
Data presentation and synthesis
Psychological distress outcomes reported in each eligible study
were classiﬁed as primary or secondary for the purposes of the re-
view. For both review questions, when multiple measures of psycho-
logical distress were assessed as outcomes, designated primary
outcomes for each study were prioritized. If there were no designated
primary outcomes, the distress measure that was used to determine4167   Unique titles/abstracts  
identified and screed 
for potential eligibility 
413    Articles selected for  
full-text review 
14      Studies included in  
systematic review of 
Review Question #1 












Fig. 1. PRISMA ﬂow diagram of study seleeligibility for the trial (Review Question #1) or as the screening tool
for psychological distress (Review Question #2) was selected. If mul-
tiple instruments were used for distress selection, continuous scores
on interview-based observer-rated instruments were prioritized
over self-rating instruments. This is because observer-rated instru-
ments, particularly the Hamilton Depression Rating Scale, are used
most often as outcome measures in depression trials and considered
the gold standard [30]. If there were no observer-rated instruments,
and there was more than 1 self-rating instrument, all were reported
as secondary outcomes. When outcomes were assessed at multiple
time points, the assessment point that followed the end of treatment
most closely was reported. Post-intervention effect sizes were reported
using the Hedges's g statistic [31], which represents a standardized dif-
ference between 2 means, as well as r2, which is statistically equivalent
[32,33], but presents results in terms of percent of variance in distress
outcomes due to treatment. Dichotomous outcomeswere not extracted
since there is no agreed upon gold standard or deﬁnition for psycholog-
ical distress “caseness.”
Eligible studies for each review question were evaluated to deter-
mine whether there was sufﬁcient clinical and methodological similar-
ity to support pooling of results. Results from trialswith a high degree of
clinically heterogeneity in terms of patients, interventions, or study pro-
cedures should not be synthesized meta-analytically because the effect
estimate that is generated would not be expected to generalize to any
given intervention [24]. For Review Question #1 (treatment), studies
were heterogeneous in terms of patient samples, therapeutic interven-
tions, outcome measures, and treatment duration. Only 1 eligibleitles/abstracts excluded: 
   No original data or case report (266)
   No cancer (668) 
   Not an RCT of distress treatment (2,740)
   < 25 randomized per group (80) 
rticles excluded: 
   No original data or case report (10) 
   No cancer (12) 
   Not an RCT of distress treatment (202) 
   No minimum level of distress (167) 
   < 25 randomized per group (7) 
   Incomplete outcome data (1) 
ction process for review question #1.
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Non-industry Mixed/mixed Sadness or anhedonia more
than half the days, plus








































































Non-industry Mixed/mixed HADS-D ≥ 8; HADS-A ≥ 10;
or MAC helplessness ≥ 12
and MAC ﬁghting
spirit ≤ 47
CBT vs. UC Total: 174





8 weeksi NAj Δ HADS-A: 0.38
(0.06–0.71)
r2 = .04 Δ
HADS-D: 0.29
(−0.03–0.61)
r2 = .02 Δ
MAC helplessness:
0.46 (0.13–0.78)




r2 = 0.03 Δ RSCL
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0.33 (0.00–0.66)
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PST vs. WL: HAMD-17:
3.76 (3.07–4.45)




PST vs. WL: BSI-GSI:
3.54 (2.87–4.21)
r2 = .76 Omega:
2.01 (1.50–2.52)
r2 = .51 POMS:
2.15 (1.63–2.67)
r2 = .54 PST-SO
vs. WL: BSI-GSI:
4.39 (3.62–5.17)
r2 = .83 Omega:
1.95 (1.44–2.46)






Industry Mixed/mixed MDD or adjustment
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r2 = .01 MADRS:
0.17 (−0.31–0.65)































































4 weekso NRj Δ SAI:o 0.22
(−0.01–0.46)




Abbreviations: BSI-GSI=Global Severity Index of the Brief Symptom Inventory; BZSDS=Brief Zung Self-Rating Depression Scale; CBT= cognitive behavior therapy; CGI-S= Clinical Global Impression Scale for Severity of Illness; CES-D=Center for
Epidemiologic Studies Depression Scale; CI = conﬁdence interval; FACT-G emotional = emotional well-being subscale of Functional Assessment of Cancer Therapy - General; HADS = Hospital Anxiety and Depression Scale total score; HADS-A =
Anxiety subscale of Hospital Anxiety and Depression scale; HADS-D=Depression subscale of Hospital Anxiety and Depression Scale; HAMD-17= 17-itemHamilton Depression Rating Scale; HAMD-21= 21-itemHamilton Depression Rating Scale;
HAS=Hamilton Anxiety Scale; HSCL-20=20-itemHopkins SymptomChecklist depression scale;MAC anxious preoccupation=anxious preoccupation subscale ofMental Adjustment to Cancer scale;MAC ﬁghting spirit= ﬁghting spirit subscale of
Mental Adjustment to Cancer scale; MAC helplessness = helplessness subscale of Mental Adjustment to Cancer scale; MADRS = Montgomery-Asberg Depression Rating Scale; MDD = major depressive disorder; NA = not applicable; NR = not
reported; PAIS psychological = psychological distress subscale of Psychosocial Adjustment to Illness Scale; PHQ-9 = 9-item Patient Health Questionnaire; POMS = Proﬁle of Mood States; PST = problem-solving therapy; PST-SO =
problem-solving therapy with signiﬁcant other; RSCL psychological = psychological symptoms subscale of Rotterdam Symptom Checklist; SAI = State Anxiety Inventory; SCL-10 anxiety = anxiety subscale derived from the Symptom
Checklist-90; SCL-20 depression= depression subscale derived from the Symptom Checklist-90; SCL-90-R GSI = Global Severity Index of revised Symptom Checklist-90; SF-12 mental =mental component summary of 12-item Short Form Health
Survey; SF-36 MHI depression: depression severity subscale of the 36-item Short Form Health Survey Mental Health Inventory; SS = social support; TQSS = Two-Question Screening Survey; Tx = treatment; UC = usual care; WL = waiting list
control; ZSRDS = Zung Self-Rating Depression Scale.
a Continuous outcomes that favored the treatment group are reported as positive numbers.
b Assessed using PHQ-9 and 3 additional questions from PRIME-MD.
c Treatment components received varied between study participants. Effects of collaborative intervention were assessed after 8 months.
d The PHQ-9 was used to determine eligibility for the trial and was thus classiﬁed as the primary outcome, but continuous outcome data were not reported for the PHQ-9.
e Enhanced usual care consisted of standard oncology care, educational pamphlets, and a listing of center and community resources.
f Results adjusted for sex, race, years in the US, dysthymia, baseline depression severity, baseline anxiety, cancer stage, cancer type, and treatment status.
g Results from social support group were not included in this review, as fewer than 25 patients were randomized to this group.
h The fourth assessment visit (mean 12.3 weeks post-randomization) was closest to the end of the treatment period. However, only 33/163 patients completed the fourth visit. Outcome data presented here were assessed at the ﬁfth visit
(mean 14.9 weeks post-randomization).
i Planned treatment duration was 8 weeks, but 28 patients (39%) received additional therapy sessions between 8 weeks and 4 months.
j No primary outcome could be identiﬁed.
k Eligible participants met study criteria for depression, cancer-related pain, or both. Results are reported only for the 309 participants meeting eligibility criteria for depression.
l Age and sex were reported for the whole sample (N = 405), and not only the 309 participants enrolled for depression.
m Treatment duration was not explicitly stated in the article, but 16 weeks was the last assessment timepoint.
n HADS-A and HADS-D were identiﬁed in the article as primary outcomes, but insufﬁcient information was provided to extract continuous outcome data. The authors reported that anxiety was signiﬁcantly reduced in the treatment group
at 16 weeks, but not depressive symptoms.














6 A. Meijer et al. / Journal of Psychosomatic Research 75 (2013) 1–17study was identiﬁed for Review Question #2 (screening). Therefore,
results were not pooled quantitatively in a meta-analysis, but were
summarized in a systematic review. A review protocol was not pub-
lished or registered for this systematic review. However, a written pro-
tocolwas developed and followed for searching, data extraction, anddata
synthesis with all methods determined a priori.
Results
Review question #1: effect of treatment of psychological distress
The combined database search for Review Questions #1 (treatment) and #2
(screening) generated 4167 unique citations. As shown in Fig. 1, for Review Question
#1 (treatment), 3754 were excluded after title/abstract review and 399 after full-text
review, leaving 14 eligible studies for review. No additional studies were identiﬁed
through alternative sources, such as hand searching of journals, forward citation of in-
cluded articles, and review of trial registries.
As shown in Table 1, the 14 studies of interventions to reduce psychological distress
we reviewed included 12 studies of patients with mixed cancer sites [34–45], 1 study
with patients with breast or cervical cancer [46], and 1 study with patients with breast
cancer only [47]. Total sample size per study ranged from 55 to 472. Of the 14 studies, 7
randomized at least 64 patients per group [35,37–40,44,45], which would provide ade-
quate (80%) power to detect a medium effect size (standardized mean difference =
0.50) [48].
Four studies were pharmacological interventions designed to treat depression, 2 with
mianserin [34,47] and 2with ﬂuoxetine [38,43]. The other 10 studies included collaborative
care interventions [35,37,40,44,46], cognitive behavior therapy [36,39,41], problem solving
therapy [42], andaromatherapymassage [45]. Among the drug trials, therewas 1 study [38]
with at least 64 patients per group, and that study found a small effect size reduction on
self-reported depressive symptomswith ﬂuoxetine (Hedges's g=0.23). Three other small-
er trials [34,43,47] reported somewhat larger effects for ﬂuoxetine (Hedges's g=0.36) [43]
and mianserin (Hedges's g = 0.60 to 0.77) [34,47]. Among collaborative care trials, effect
sizes were small to moderate for adequately powered trials (Hedges's g = 0.17 to 0.47)
[35,37,40,44] andmoderate to large for a smaller study (Hedges's g=0.60) [46]. The effect
sizes for outcomes reported in a trial of problem-solving therapy trial [42], comparing
problem-solving therapy to await-list control (Hedges's g=3.76) or problem-solving ther-
apy with a signiﬁcant other to the wait-list control (Hedges's g= 4.30) were exceedingly
large. The effect sizes on 2 outcome measures from aromatherapy with massage [45]
were small (Hedges's g = 0.17 to 0.22) and not statistically signiﬁcant. Effect sizes for
each individual study are shown in Table 1.
Risk of bias ratings are shown in Table 2, and speciﬁc explanations for all ratings
are available from the authors. Among the 4 trials of antidepressants, all had unclear
or high risk of bias for the majority of rating categories [34,38,43,47]. Speciﬁcally, all
had unclear or high risk related to industry funding and author-industry ﬁnancial
ties, and all were conducted prior to the availability of clinical trial registries. Thus,
selective outcome reporting was rated as unclear for all of these trials. Among
non-pharmacological treatments, all were rated as high risk for blinding of patients
and personnel and for blinding of outcome assessment due to the nature of the inter-
ventions and outcome assessments. Generally, quality was mixed in these studies. Not
including blinding, only 1 non-pharmacological intervention trial [44] was rated as low
risk of bias across all categories, including being registered with sufﬁciently precise
outcome registration to compare to those described in the published trial report. One
trial of problem-solving therapy [42] was rated as high risk of bias for Other Sources
of Bias. This was due to the unrealistically high effect sizes, approximately 10 times
those of other non-pharmacological studies, which were reported for the primary out-
come variable. Other meta-analyses have excluded this study as an extreme outlier
[49–51].
Review question #2: effect of screening for psychological distress
For Review Question #2, 4142 of the original 4167 citations were excluded after
title and abstract review and 24 after full text review, leaving 1 RCT [52] of screening
for psychological distress among newly diagnosed breast cancer patients (Fig. 2). In
this study, the usual care group (N = 127) received a brief psychosocial intervention
in the ﬁrst 2 weeks post-randomization as part of standard care (mean 2.2 social
work contacts). The intervention group (N = 123) received the same brief interven-
tion (mean 2.4 social work visits) plus telephone screening with the General Health
Questionnaire, beginning 21 days post-randomization and continuing monthly for 12
months. Once screening was initiated, 80% of screened patients had at least 1 positive
screen, which triggered a social work telephone contact beyond referrals that occurred
as part of usual care (mean = 6.1 social work contacts versus 2.4 for usual care). As
shown in Table 3, at 12 months post-randomization, Psychiatric Symptom Index scores
for the intervention and usual care groups were equivalent. In addition, women in the
intervention group were somewhat more likely to have a diagnosis of MDD at 12
months post-randomization (n = 22, 18%) compared to women in the control group
(n= 15, 12%), although this was not statistically signiﬁcant. Risk of bias in this screening
RCT was generally low (Table 2).
A number of other studies (see Table 4) described by their authors or in other re-
views [10–12] as related to screening were excluded from the present systematicreview. Several studies were excluded because decisions about whether patients
should receive further assessment, referral, or treatment were not based on a
pre-speciﬁed cutoff score on a measure of distress. In those studies, a range of screen-
ing tools was often made available for clinical consultations, but a positive screen on a
distress screening tool was not used to determine referral for psychosocial evaluation
or treatment. Studies were also excluded because they (1) were not RCTs; (2) included
multiple screening tools for many practical or logistical issues, not allowing the effect of
screening for psychological distress to be evaluated separately; or (3) did not report
distress symptom or diagnosis outcomes.Discussion
Several clinical recommendations [4–6] have beenmade for screening
for psychological distress to be part of standard cancer care. Guidelines
and recommendations, however, vary in the degree to which they are
evidence-based [53] and none of these recommendation statements
have been based on a systematic review that found beneﬁts from
screening, deﬁned according to standard deﬁnitions.
There are well-established procedures for evaluating screening pro-
grams [8,16,17]. The principal criterion is whether there is evidence
fromwell-conducted RCTs that beneﬁts from screening outweighpossi-
ble harms (e.g., economic costs, drug side effects). The main ﬁndings of
this systematic review are that (1) treatment of distress with pharma-
cological or behavioral interventions can improve psychological distress
in adult cancer patients with psychological distress; and that (2) only 1
RCT of distress screening, with screening deﬁned based on standard
deﬁnitions of medical screening has been conducted with adult cancer
patients. In that study [52] of telephone screening for psychological
distress among newly diagnosed breast cancer patients, monthly
telephone screening did not improve psychological distress. The
authors of that study concluded that a brief psychosocial interven-
tion, which was provided as part of standard care, may have reduced
distress and reduced the potential impact of screening. Additionally,
the fact that 80% of patients in that study had at least 1 positive screen
in a 12-month period suggests that screening may not have effectively
identiﬁed patients with substantially elevated distress.
Several reviews on screening for distress in cancer patients have
been published previously [10–12] and they each concluded that
there was no evidence that distress screening improved distress out-
comes among cancer patients. Two of these reviews included 7 studies
[10,12], and one included 14 studies [11]. The authors of those studies
were consistent in arguing that evidence for beneﬁts of screening for
distress on patient outcomes in cancer patients is inconclusive and
scarce and in calling for high-quality trials to determine if distress
screening would improve patient outcomes.
Two of the reviews [10,11] concluded that there is evidence that the
use of distress questionnaires may improve communication about psy-
chosocial issues between patients and oncology staff. It is important to
keep inmind, however, that using questionnaires to facilitate conversa-
tions with patients, while potentially helpful, is not screening and does
not inform the question of whether screeningwith these tools to deter-
minewho receives subsequent assessmentwill beneﬁt patients. Consis-
tent with this, a major shortcoming of previous reviews on distress
screening [10–12] is that they all included studies that would not be
considered trials of screening interventions in the context of any stan-
dard deﬁnition of medical screening. Indeed, with the exception of 1
study [52], all of the studies included in these reviews were excluded
from the current review for a number of reasons (see Table 4 for exclud-
ed distress screening studies). Five studies [26,54–57] screened formul-
tiple problems at the same time (i.e., fatigue, pain, perceived support,
and psychological distress), which made it impossible to assess the
speciﬁc effects of screening for psychological distress. One of those
studies [26] screened simultaneously for multiple problems with
substantially different possible care responses (e.g., psychological dis-
tress, pain, fatigue, weight change, transportation, parking, drug cover-
age, ﬁnances). It was not possible, however, to determine in this
study how many patients screened positive for psychological distress
Table 2
Assessment of risk of bias in randomized controlled trials in review question #1 (treatment) and review question #2 (screening)





























Review question #1 (treatment)




Unclear risk Unclear risk Unclear risk Low risk
Dwight-Johnson,
2005 [46]




Unclear risk Low risk Unclear risk Low risk




Unclear risk Low risk Low risk Low risk




Unclear risk Low risk Low risk Low risk




Unclear risk Low risk Low risk Low risk




Unclear risk Unclear risk Unclear risk Unclear riska




Unclear risk Low risk Low risk Low risk
Kroenke, 2010
[40]




Unclear risk Low risk Unclear risk Low risk
Moorey, 2009
[41]




Unclear risk Low risk Low risk Low risk




Unclear risk Low risk Low risk High risk
Razavi, 1996
[43]




Unclear risk Unclear risk High risk Low risk
Strong, 2008
[44]




Low risk Low risk Low risk Low risk
Van Heeringen,
1996 [47]




Unclear risk High risk Unclear risk Low risk
Wilkinson, 2007
[45]




Unclear risk Low risk Low risk Low risk
Review question #2 (screening)
Maunsell, 1996
[52]




Low risk Low risk Low risk Low risk
a Authors of study did not provide data on number of patients who were approached or eligible for the trial, but they did not that the patients enrolled represented a small
fraction of eligible patients.
b Effect sizes reported are much higher than seen in any other psychotherapy trials of this size and larger than normally considered plausible. This trial has been excluded as an
extreme outlier in other reviews [47–49].
7A. Meijer et al. / Journal of Psychosomatic Research 75 (2013) 1–17versus other practical or logistical issues, such as difﬁculties with trans-
portation, parking, drug coverage, or ﬁnances, none of which would be
best managed through psychological intervention. Six studies [55–60]
did not use a deﬁned cutoff score to indicate a positive screen for
heightened distress or to determine which patients would receive fur-
ther assessment or treatment. In addition, 6 of the studies [58,60–64]
were not RCTs, butwere, for example, sequential cohort designs. Finally,
3 of the studies [62–64] did not assess distress as an outcome, but inves-
tigated other outcomes, such as referral rates.
Distress screening can beneﬁt patients only to the extent that it
identiﬁes patients with signiﬁcant psychological distress who are
not already recognized as distressed or receiving supportive services,
successfully engages those patients in treatment, and achieves posi-
tive treatment results. In many cancer care settings, however, high
numbers of patients are already treated with antidepressants as an at-
tempt to address distress, even though many of these patients do not
have depression or a history of depression [65]. Furthermore, as illus-
trated by one study from Austria [66], the desire for psychosocial sup-
port to cope with cancer may not be correlated with distress levels,
and nearly as many patients with low levels of distress may desire
supportive care as patients above the cutoff criterion on a screening
tool. Thus, better patient psychosocial care may be best achieved by pro-
viding more information and coordinating care pathways, rather than
seeking to automate triage processes through mechanized screening
and numerical algorithms.Beyond screening for distress in cancer care settings, a number of
other systematic reviews have concluded that there are no RCTs that
have shown that depression screening improves depressive symptoms
in cancer [13], cardiovascular disease [67], or perinatal care [68]. A 2008
meta-analysis of depression screening in primary care [69] reviewed 11
trials and found several trials where screening increased identiﬁcation
or treatment of depression, but none where screening improved de-
pression outcomes. The U.S. Preventive Services Task Force has
recommended depression screening in primary care [70], but speciﬁes
that screening should only occur when integrated depression care
systems for evaluation and case management are available. No trials,
however, have shown that patients screened and referred for such col-
laborative care would have better outcomes than patients who are not
screened, but who could potentially access collaborative care via other
pathways [9]. This was an important reason why the UK National Insti-
tute of Clinical Excellence [71] did not recommend routine depression
screening in primary care.
Given the current lack of evidence for beneﬁts of distress screen-
ing, potential costs from implementing such a program must be care-
fully considered. An important concern is that routine screening
would either take time or consume resources that could be devoted
to other patient needs. Some might assume that screening question-
naires are easily and inexpensively implemented. However, this con-
fuses the cost of administering a questionnaire and the cost of
screening. The cost of screening includes assessments, consultations,
4167   Unique titles/abstracts  
identified and screened 
for potential eligibility 
25        Articles selected for  
full-text review 
1          Study included in  
systematic review of 
Review Question #2 
4142   Titles/abstracts excluded: 
•   No original data or case report (266) 
•   No cancer (668) 
•   Not an RCT of distress screening (3,208) 
24       Articles excluded: 
•   No cancer (2) 
•   Not an RCT of distress screening (22) 
Fig. 2. PRISMA ﬂow diagram of study selection process for review question #2.
8 A. Meijer et al. / Journal of Psychosomatic Research 75 (2013) 1–17treatment and follow-up services, which is much larger than the cost
of administering a questionnaire [7,8].
Another concern is that attention and potentially limited mental
health resources could be devoted only to those who screen positive
for distress even though many other patients might like to discuss
their psychosocial needs or might have self-referred or been referred
by their clinicians. It is important that the psychological needs of cancer
patients are recognized and addressed, and there are many alternatives
to screening to meet this need. As long as there is no evidence that
screening leads to improvements in distress, focusing on the availability
and implementation of psychosocial support might better beneﬁt cancer
patients.
Without high-quality evidence from well-designed RCTs that
demonstrate sufﬁcient beneﬁt to justify costs and potential harms
from screening, recommendations for implementation of screening
programs are premature. Research is needed that compares the beneﬁts
and harms of screening for psychological distress in trials in which pa-
tients in the screening group may access psychosocial resources via
screening or other referral processes and patients in the non-screened
group can access the same services via self- or other referral processes.
Trials should clearly differentiate psychosocial needs that are best
managed in the context of mental health services versus practical
or logistical issues that are best addressed via other mechanisms
(e.g., parking, insurance). They should also differentiate problems,
such as fatigue and pain, which may or may not be related to psycho-
logical issues and for which ﬁrst-line interventions are usually not
psychological, from psychological distress.Funding/support
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Appendix A. Search strategy for Review Questions #1 and #2
Pubmed
(Depression [MeSH] OR “depressive disorder” [MeSH] OR “major
depressive disorder” [MeSH] OR distress [tiab] OR anxiety [MeSH])
OR “quality-of-life” [title]) AND (“mass screening” [MeSH] OR screen*
[tiab] OR assess* [tiab] OR “drug therapy” [MeSH] OR “antidepressive
agents” [MeSH] OR antidepress* [tiab] OR SSRI [tiab] OR anti-anxiety
agents [MeSH]ORpsychotherapy [MeSH]OR psychologic [tiab] OR treat-
ment [tiab]OR “treatment outcome” [MeSH]) AND (cancer [MeSH] OR
neoplasms [MeSH] OR malignancy [tiab] OR tumor [tiab] OR tumour
[tiab] OR oncolog* [tiab])
Humans, clinical trial, randomized controlled trial, all adults: 19+
years
Cochrane
#1 MeSH descriptor depressive disorder explode all trees
#2 MeSH descriptor depression




#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8 MeSH descriptor mass screening explode all trees
#9 MeSH descriptor psychotherapy explode all trees
#10 MeSH descriptor treatment outcome explode all trees
#11 MeSH descriptor antidepressive agents explode all trees






#18 (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR
#16 OR #17)





#24 (# 19 OR #20 OR #21 OR #22 OR #23)
#25 (#7 AND #18 AND #24)
#26 (randomized AND controlled AND trial): publ.type
#27 (#25 AND #26)
Table 4
Excluded studies for effect of screening on psychological distress outcomes (review question #2)
First author, year, country Cancer site N consented/
randomizeda
Comparison Distress outcomes Reason(s) for exclusion
Berry, 2011, USA [72] Mixed 660 Intervention: Patients completed a quality of life
questionnaire, ESRA-C. A summary of the results,
with symptoms above a predetermined threshold
ﬂagged, was provided to the clinician prior to visit.
Control: Patients completed a quality of life
questionnaire, the ESRA-C. No summary of the
results was provided to the clinician.
Only number of PHQ-9 symptoms and
EORTC QLQ-C30 emotional function symptoms
discussed with clinician, but not distress
outcomes were assessed.
A positive distress screen based on a deﬁned
cutoff score was not used to determine who
received further assessment or treatment.
Distress symptoms were not an outcome, only
the discussion of symptoms.
Boyes, 2006, Australia [54] Mixed 80 Intervention: Results from a computer survey
completed prior to
each visit were provided to the patient's oncologist.
The survey included and assessment of 12 physical
symptoms associated with chemotherapy, symptoms
of anxiety and depression (HADS), and perceived
supportive care needs (31 items), along with
computer-generated suggested strategies to manage
each identiﬁed issue.
Control: Results from computer survey not made
available to oncologist.
No signiﬁcant difference after 4 visits between
groups for change in HADS-D scores and proportion
of patients with HADS-D ≥ 11.
Screening of multiple problems and perceived
care needs did not allow assessment of the effect
of distress screening. In addition, a positive distress
screen based on a deﬁned cutoff score was not




Mixed 129 Intervention: Patients were offered the possibility
of psychosocial support by head nurse and
information leaﬂet. Those who accepted were
screened using a semi-structured interview with
a checklist. Results were discussed in an interview,
and patients were asked if they wanted a
follow-up contact.
Control: Usual care with no screening.
No signiﬁcant difference between groups on
EORTC QLQ-C30 emotional functioning subscale,
IES total score or GHQ-12 total score.
Not a randomized controlled trial (sequential
cohort design). A positive distress screen based
on a deﬁned cutoff score was not used to determine
who received further assessment or treatment,
which was based on whether patients requested
it following an interview.
Carlson, 2010, Canada [26] Lung and breast 1134 Full screening intervention: Results from DT,
problem checklist, fatigue and pain thermometers,
and PSSCAN, depression and
anxiety sections, along with personalized
feedback report placed on patient's electronic
medical record at initial visit.
Triage intervention: Full screening, as described
above, along with an offer to speak to a member
of the study psychosocial team about any of the
assessed issues.
Control: DT completed, but results were not
disclosed to patient
or placed on electronic medical record.
No difference between full screening intervention,
triage intervention, or usual care groups on PSSCAN
depression scores 3 months post-randomization.
Screening of multiple problems did not allow
assessment of the effect of distress screening.
Detmar, 2002,
Netherlands [59]
Mixed 273b Intervention: Patients completed a quality of life
questionnaire, the EORTC QLQ-30, at 3 successive
outpatient visits with results
made available to patient and physician prior to
consultation.
Control: Usual care.
No difference between groups in SF-36 Mental
Health subscale after 4th visit.
A positive distress screen based on a deﬁned
cutoff score was not used to determine who
received further assessment or treatment.
Grassi, 2011, Italy [61] Mixed 3375c Intervention: Following a staff educational
intervention, the DT was introduced into clinical
practice, with referral to psycho-oncology
services for assessment and intervention
following positive screens (DT >4).
Control: Physicians and nurses were able to refer
patients to psycho-oncology services based on
clinical judgment.
Only proportion of patients referred to psycho-oncology
services and characteristics of referred patients
were reported, but not distress outcomes.
Not a randomized controlled trial. In addition,
distress was not an outcome. Only proportion of















First author, year, country
Cancer site N consented/
randomizeda
Comparison Distress outcomes Reason(s) for exclusion
Hilarius, 2008,
Netherlands [58]
Mixed 298 Intervention: Patients completed a quality of life
questionnaire, the EORTC QLQ-30, at 4 outpatient
visits, with summaries given to patients and
nurses prior to consultation.
Control: Standard consultations with physicians
and nurses.
No difference between groups in SF-36 Mental Health
subscale at 4th visit.
Not a randomized controlled trial (sequential
cohort design). In addition, a positive distress
screen based on a deﬁned cutoff score was not used
to determine who received further assessment
or treatment.
Ito, 2011, Japan [64] Mixed 998 Intervention: The pharmacist administering
chemotherapy administered the DIT. Patients
scoring above cutoff (≥4 distress; ≥3 impact)
were recommended for consultation at psychiatry
service. Those who refused were offered detailed
information on self-management of mental health
and were monitored. Feedback of distress results
was provided on patients' medical charts.
Control: Usual care with no screening
No difference in proportion of patients referred to
Psychiatry Service. Shorter period between ﬁrst
chemotherapy visit and visit to Psychiatry Service
for intervention group.
Not a randomized controlled trial (retrospective
cohort design). In addition, distress was not an
outcome. Outcomes were proportion of patients
referred to psychiatry service and treated for
depression or anxiety, and number of days from




Mixed 450 Intervention: Patients at their ﬁrst consultation
completed a series of self-report questionnaires
via touch-screen computer, including the CNQ,
EORTC QLQ-C30, and BDI-SF. A summary of
questionnaire results was made available to
physicians prior to consultation, which were
intended to be used to inform an individualized
management plan.
Control: Questionnaire responses were not made
available to health care team prior to consultation.
No signiﬁcant difference between groups at 2 months
or 6 months post-randomization for the CNQ
psychological domain, BDI-SF scores or EORTC QLQ-C30
Emotional Functioningd
A positive depression screen based on a deﬁned
cutoff score was not used to determine who received
further assessment or treatment. In addition, screening
of multiple problems did not allow assessment of the
effect of depression screening.
Rosenbloom, 2007, USA [56] Mixed 213 Assessment, interview, and discussion intervention:
At baseline, 1 and 2 months, patients completed
FLIC and FACT-G, and FACT-G
scores were elaborated through an interview and
discussion, the results of which were shared with
the treatment nurse prior to visit.
Assessment intervention: At baseline, 1 and 2
months, patients completed FLIC and FACT-G,
and FACT-G scores were shared with the treatment
nurse prior to visit.
Control: Patients completed FLIC at baseline.
Questionnaire data not shared with the treatment
nurse.
No signiﬁcant difference between groups at 3 months
or 6 months post-randomization for Brief POMS negative
mood subscale or FLIC psychological subscale scores.
A positive distress screen based on a deﬁned cutoff
score was not used to determine who received further
assessment or treatment. In addition, screening of
multiple problems did not allow assessment of the
effect of distress screening.
Sarna, 1998, USA [74] Lung 48 Intervention: Patients completed questionnaires at
a number of times, including the SDS and HADS.
A summary of results was given to the nurse, who
identiﬁed problems and proposed interventions.
Control: Patients completed questionnaires at a
number of times, including the SDS and HADS.
No summary of results was given to the nurse
SDS scores increased for the control group, but did
not increase for the intervention group.
A positive distress screen based on a deﬁned cutoff
score was not used to determine who received further
assessment or treatment.
Shimizu, 2010, Japan [63] Mixede 1065 Intervention: Patients completed 11-point DIT
(score range 0–10), and those with a distress
score ≥ 4 and an impact score ≥ 3 were referred
by their oncologist for a psycho-oncology service
consultation.
Control: Usual care with referral to psycho-oncology
services by physician of patients considered
moderately or severely distressed.
Only number of positive screens and number diagnosed
and treated, but not depression outcomes, were assessed.
Not a randomized controlled trial (sequential cohort
design). In addition, outcomes included number of
positive screens and number treated, but no distress
outcomes were assessed.
Taenzer, 2000, Canada [60] Lung 57 Intervention: At a single clinic visit, patients
completed the EORTC QLQ-C30, which was
provided to clinic staff prior to clinic appointment
with no speciﬁc instructions for use.
Control: Patients completed the EORTC QLQ-C30
Only number of quality of life issues addressed
in appointment and patients satisfaction, but no
depression outcomes, were assessed.
Not a randomized controlled trial (sequential cohort
design). In addition, a positive distress screen based
on a deﬁned cutoff score was not used to determine
who received further assessment or treatment and
no distress outcomes were assessed.















First author, year, country Cancer site N consented/
randomizeda
Comparison Distress outcomes Reason(s) for exclusion
Thewes, 2009, Australia [62] Mixed 83 Intervention: Patients completed the DT, and
nursing staff was encouraged to assess problems
and discuss psychosocial referral for patients
with DT score ≥ 5.
Control: Usual care with no screening.
Contrary to hypothesis, patients in the screened
group reported signiﬁcantly higher level of unmet
needs 6 months after initial clinic contact.
Not a randomized controlled trial (sequential
cohort design). Outcome of unmet psychosocial
needs, but not distress.
Velikova, 2004, UK [56] Mixed 286 Assessment and feedback intervention: For a
6 month study period, prior to clinic visits, patients
completed the EORTC QLQ-C30 and HADS with
results provided to physicians prior to visit.
Attention control: For a 6 month study period,
prior to clinic visits, patients completed the
EORTC QLQ-C30 and HADS with no results
provided to physicians.
Usual care control: Patients did not complete EORTC
QLQ-C30 or HADS.
Scores on FACT-Emotional Subscale were better in
the intervention group than the usual care group,
but not different from the attention control group.
A positive distress screen based on a deﬁned cutoff
score was not used to determine who received further
assessment or treatment. In addition, screening of
multiple problems did not allow assessment of the
effect of distress screening.
Abbreviations: BDI-SF = Beck Depression Inventory - Short Form; CNQ = Cancer Needs Questionnaire; DIT = Distress and Impact Thermometer; DT = Distress Thermometer; EORTC QLQ-C30 = European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire - Core 30; ESRA-C = Electronic Self-report Assessment - Cancer; FACT - emotional = Functional Assessment of Cancer Therapy - emotional; FACT-G = Functional Assessment of Cancer
Therapy - General; FLIC = Functional Living Index - Cancer; GHQ = General Health Questionnaire; HADS = Hospital Anxiety and Depression Scale; HADS-D = Depression subscale of Hospital Anxiety and Depression scale; IES = Impact
of Event Scale; MDD = Major depressive disorder; PHQ = Patient Health Questionnaire; PL = Problem List; POMS = Proﬁle of Mood States; PSI = Psychiatric Symptom Index; PSSCAN = Psychological Screen for Cancer; SDS = Symptom
Distress Scale; SF-36 = Short Form - 36 Health Survey Questionnaire.
a Number consented for non-randomized controlled trials and number randomized for randomized controlled trials.
b Physicians, rather than patients, were randomized. This number is the number of eligible patients who agreed to participate.
c Includes 2268 newly diagnosed cancer patients seen in an oncology department prior to introducing a DT and 1107 following introduction of the DT.
d The authors reported a post-hoc subgroup analysis that found signiﬁcantly improved BDI-SF scores for the 44 patients in the intervention group with baseline BDI-SF scores ≥ 8 compared to the 19 control patients with BDI SF ≥ 8.
However, patients were not randomized based on BDI-SF scores, and the relevance of these results for screening is not clear, since screening is applied to all patients, not only patients identiﬁed through screening with high scores.
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S1 1. “major depression” MMOR 2. “depression (emotion)” MM
OR 3. depress* TI
OR 4. distress MM
OR 5. distress TI
OR 6. anxiety MJ
OR 7. anxiety TI
OR 8. quality of life MJ
OR 9. quality of life TI
S2 1. “screening tests” MM
OR 2. screening MM
OR 3. screen* TI
OR 4. screen* AB
OR 5. assess* TI
OR 6. treatment MJ
OR 7. intervention TI
OR 8. intervention AB
OR 9. antidepressant drugs MM
OR 10. antidepress* TI
OR 11. drug therapy MM
S3 1. neoplasms MJ
OR 2. cancer TI
OR 3. cancer AB
OR 4. tumor TI
OR 5. tumor AB
OR 6. tumour TI
OR 7. tumour AB
OR 8. oncol* TILimit to humans, adulthood (18yrs & older)
Treatment outcome/clinical trial
CINAHL
S1 1. depression MMOR 2. depress* TI
OR 3. depress* AB
OR 4. distress MJ
OR 5. distress TI
OR 6. distress AB
OR 7. anxiety MM
OR 8. anxiety TI
OR 9. anxiety AB
OR 10. “quality-of-life” MM
OR 11. “quality-of-life” TI
S2 1. screening MJ
OR 2. screen* TI
OR 3. assess* TI
OR 4. psychotherapy MJ
OR 5. treatment TI
OR 6. therapy TI
OR 7. intervention TI
S3 1. neoplasms MM
OR 2. cancer TI
OR 3. cancer AB
OR 4. tumor TI
OR 5. tumour TI
OR 6. oncol* TI
Limit to humans, exclude Medline, all adult
S4 S1 AND S2 AND S3Embase
1. depression/mj OR “distress syndrome”/mj OR distress:ti,ab OR
anxiety/mj OR anxiety:ti,ab OR ‘quality of life’/exp/mj
2. screening/mj OR screen*:ti,ab OR assess*:ti,ab OR therapy/mj
OR “intervention study”/mj OR “antidepressant agent”/mj OR
antidepress*:ti,ab OR psychotherapy/mj OR treatment:ti,ab
3. neoplasm/mj OR cancer:ti,ab OR tumor:ti,ab OR tumour:ti,ab OR
oncol*:ti,ab
4. 1 and 2 and 3
Map to preferred terminology, include sub-terms/derivatives
(explosion search), search terms must be of major focus in articles
found, humans, adult and aged (18 to 64 and 65+ years), controlled
clinical trial, randomized controlled trial, Embase only.
ISI
1. TS=(major depressive disorder) OR TS=depression OR TS=distress
OR TI=distress OR TS=anxiety OR TI=anxiety OR TI=(quality of
life)
2. TS=screening OR TI=screen* OR TI=assess* OR TS=drug therapy
OR TI=intervention OR TI=treatment OR TI=pharmacological OR
TI=psychological OR TI=antidepress* OR TI=psychotherapy OR
TI=effect*
3. TS=neoplasms OR TI=neoplasm* OR TI=malignan* OR TI=cancer
OR TI=tumor OR TI=tumour OR TI=oncol*
4. TS=controlled
5. #1 AND #2 AND #3 AND #4
Scopus
TITLE-ABS-KEY (“major depressive disorder” OR depress* OR dis-
tress OR anxiety OR “quality of life”) AND TITLE-ABS-KEY (screen*
OR assess* OR treatment OR “drug therapy” OR intervention OR
antidepress* OR psychotherapy OR treatment OR psychologic*)AND
TITLE-ABS-KEY (neoplasm* OR cancer OR malignan* OR tumor OR
tumour OR oncol*) AND (TITLE-ABS-KEY (randomized OR controlled
OR trial))
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Appendix D. Coding Manual
Review Question #1: Distress treatment
Original data: The article must be an original report of a study, and
not, for example, a letter, editorial, systematic review or meta-analysis,
or a case series or case report study.
(Adult) cancer: The study sample must consist of cancer patients or
survivors of cancer and not, for example, concern partners of cancer
patients. When the sample includes cancer patients as well as other
patients, data for cancer patients must be separately reported. Only
studies on adult patients (≥ 18 years) will be included.
RCT of distress reducing intervention: The study needs to be a ran-
domized controlled trial of treatment designed to reduce general or psy-
chological distress as opposed to medical treatments aimed primarily at
treating a physical symptom (e.g., pain, fatigue). Studies can also address
treatment-speciﬁc distress, such as distress related to chemotherapy or
radiation therapy. Treatments can be pharmacological, psychotherapeu-
tic, or other. A distress treatment group has to be compared to a control
group. Studies that are head-to-head comparison studies of two active
treatments are not included. Only studies with placebo, standard care,
or attention control are included. Studies with enhanced standard care
(such as providing information to patients and/or physicians) can be in-
cluded. Studieswith control groups inwhich there is any active interven-
tion, such as getting attention from a provider even if the attention was
hypothesized to be inert, are excluded. Distress must be an outcome of
the trial. Distress outcomemeasures can be anymeasure of generalmen-
tal health, distress, or depression.
The following paradigm is a guide for deciding whether or not an
intervention is intended to reduce distress. If a study meets at least
one of the following 3 criteria, we would count it as an intervention
designed to reduce psychological distress:
(1) The declared primary outcome is psychological distress
(e.g., symptoms of distress, depression, anxiety, mental health
function), and the intervention is not a medical treatment
aimed primarily at treating the cancer (e.g., chemotherapy).
15A. Meijer et al. / Journal of Psychosomatic Research 75 (2013) 1–17Note: If a study claims that its primary objective/outcome is to
improve survival via reducing psychological distress, then count
this as an intervention designed to reduce psychological distress.
(2) There are multiple outcomes declared without identiﬁcation of a
primary outcome, some of which are psychological and some of
which are not primarily psychological (e.g., physical health or
quality of life, fatigue, pain). However, the mechanism of the in-
tervention is known to primarily target cognitions and behav-
iours related to mood/psychological distress or to target
physiological indices of stress that are known to be related to
mood/psychological distress. Examples of interventions whose
mechanism is known to primarily target cognitions and behav-
iours related tomood/psychological distress include psychological
therapies (e.g., CBT, psychodynamic therapy, behavioural therapy,
expressive writing) that can be delivered via a variety of mecha-
nisms (psychotherapy, bibliotherapy, online resources, group
delivery). Coping oriented interventions would be included, as
well, as coping implies a psychological component. Examples of
interventions that target physiological indices of stress that are
known to be related tomood/psychological distress include relax-
ation training, hypnosis, imagery/guided imagery, stress manage-
ment, breathing training). Examples of interventions that would
not meet this deﬁnition include exercise, yoga, enhanced nursing
care. Note however, that all of these interventions could be
included if they meet criterion 1 or 3.
(3) Criteria #1 (primary outcome) and #2 (intervention charac-
teristics) are not met, but entry into the trial depends on
meeting a threshold criteria for psychological distress, Examples
of interventions in this category might include exercise, yoga,
and enhanced nursing care.
Minimum level of distress: In addition, the study must include pa-
tients with a minimum level of general, psychological or emotional dis-
tress and must exclude patients scoring below that level, or studies
must perform separate analyses on patients with distress scores above
a cutoff level. Inclusion standards may include a self-report question-
naire or a clinical interview (structured or unstructured) for depression
or anxiety disorders. Studies that do not provide separate analyses for
patients above a distress cutoff, but, instead, analyze the association
between distress and treatment outcome continuously are excluded.
Authors will not be contacted for original data if the sample was not di-
chotomized in the study.
Sample size: There must be at least 25 subjects randomized to each
group (distressed vs. non-distressed).
Complete distress outcome data: Outcomes have to be continuous,
or a dichotomous response or remission outcome based on deﬁned
criteria must be reported.
Review Question #2: Distress screening
Original data: The article must be an original report of a study, and
not, for example, a letter, editorial, systematic review or meta-analysis,
or a case series or case report study.
(Adult) cancer: The study sample must consist of cancer patients or
survivors of cancer and not, for example, concern partners of cancer
patients. When the sample includes cancer patients as well as other
patients, data for cancer patients must be separately reported. Only
studies on adult patients (≥ 18 years) will be included.
RCT of screening for distress: The study needs to be a randomized
controlled trial in which the intervention group patients are screened
for distress with any measure or screening method and the control
group is not screened. A cutoff on a distress screening tool that would
be used to identify possible cases and make decisions regarding further
assessment or treatment needs to be deﬁned a priori. Studies in which
questionnaire results were provided to clinicians without guidance on
cutoff scores to determine positive screening status are also excluded.Studies in which both intervention and control groups received the
same psychosocial services, but service providers in the intervention
group had access to results from psychosocial questionnaires that may
have informed their interactions, but did not necessarily determine
service allocation decisions, are excluded. Studies that administered
multiple screening tools for multiple problems may be included if all
of the measures have deﬁned cutoffs for positive screens and all are
screens for psychological or general distress. General or psychological
distress must be an outcome of the study. Distress outcome measures
can be any measure of general mental health, distress, or depression.
When distress is measured, but is not an outcome variable of the
study (but a predictor or mediator, etc.) studies are excluded.





Distress inclusion criterion and cutoff threshold
Treatment condition
Control condition
N randomized, n treatment, n control
Mean age
Percentage males
Number and percentage lost to follow-up
Treatment duration
Distress outcomes (continuous primary and secondary outcomes):
Hedges's g (95% CI) and r2
Study funding source
Appendix F. Cochrane Risk of Bias Tool
Sequence generation: Describe the method used to generate the
allocation sequence in sufﬁcient detail to allow an assessment of
whether it should produce comparable groups.
Allocation concealment: Describe the method used to conceal the
allocation sequence in sufﬁcient detail to determine whether interven-
tion allocations could have been foreseen in advance of, or during,
enrolment.
Blinding of participants, personnel and outcome assessors:
Assessments should bemade for eachmain outcome (or class of outcomes).
Describe all measures used, if any, to blind study participants and per-
sonnel from knowledge of which intervention a participant received.
Provide any information relating to whether the intended blinding
was effective.
Incomplete outcome data: Assessments should be made for each
main outcome (or class of outcomes). Describe the completeness of out-
come data for each main outcome, including attrition and exclusions
from the analysis. Statewhether attrition and exclusionswere reported,
the numbers in each intervention group (compared with total random-
ized participants), reasons for attrition/exclusions where reported, and
any re-inclusions in analyses performed by the review authors.
Selective outcome reporting: State how the possibility of selec-
tive outcome reporting was examined by the review authors, and
what was found.
Pharmaceutical industry funding: State the funding source(s) of
the trial, or indicate if the trial funding source was not reported.
Author-industry ﬁnancial ties and/or employment: State whether
any trial authors disclosed ﬁnancial ties and/or employment by the
pharmaceutical industry, or if author-industry ﬁnancial ties or afﬁlia-
tion were not reported.
Other sources of bias: State any important concerns about bias not
addressed in the other domains in the tool. If particular questions/
entries were pre-speciﬁed in the review's protocol, responses should
be provided for each question/entry.
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